Pathogenesis of systemic inflammatory diseases in childhood: “Lessons from clinical trials of anti-cytokine monoclonal antibodies for Kawasaki disease, systemic onset juvenile idiopathic arthritis, and cryopyrin-associated periodic fever syndrome”

References

• Si-Tahar M, Touqui L, Chignard M. Innate immunity and inflammation – two facets of the same anti-infectious reaction. Clin Exp Immunol. 2009;156(2):194–8.
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805–20.
   PubMed Web of Science ®Google Scholar
• Saitoh T, Akira S. Regulation of innate immune responses by autophagy-related proteins. J Cell Biol. 2010;189(6):925–35.
   PubMed Web of Science ®Google Scholar
• Germain RN, Robey EA, Cahalan MD. A decade of imaging cellular motility and interaction dynamics in the immune system. Science. 2012;336(6089):1676–81.
   PubMed Web of Science ®Google Scholar
• Kumar H, Kawai T, Akira S. Pathogen recognition in the innate immune response. Biochem J. 2009;420(1):1–16.
   PubMed Web of Science ®Google Scholar
• Pedra JHF, Cassel SL, Sutterwala FS. Sensing pathogens and danger signals by the inflammasome. Curr Opin Immunol. 2009; 21(1):10–16.
   PubMed Web of Science ®Google Scholar
• Oicard C, Casanova JL, Puel A. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IkBα deficiency. Clin Microbiol Rev. 2011;24(3):490–7.
   PubMed Web of Science ®Google Scholar
• Savic S, Dickie LJ, Battellino M, McDermott MF. Familial Mediterranean fever and related periodic fever syndromes/autoinflammatory diseases. Curr Opin Rheumatol. 2012;24(1):103–12.
   PubMed Web of Science ®Google Scholar
• Castillo L, Carcillo J. Secondary hemophagocytic lymphohistiocytosis and severe sepsis/systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med. 2009;10(3):387–92.
   PubMed Web of Science ®Google Scholar
• Jin B, Sun T, Yu XH, Yang YX, Yeo AE. The effects of TLR activation on T-cell development and differentiation. Clin Dev Immunol. 2012; doi: 10.1155/2012/836485
   Google Scholar
• Notarangelo LD, Fischer A, Geha RS, Casanova JL, Chapel H, Conley ME, et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol. 2009;124(6):1161–78.
   PubMed Web of Science ®Google Scholar
• Harden LM, Plessis ID, Poole S, Laburn HP. Interleukin(IL)-6 and IL-1β act synergistically within the brain to induce sickness behavior and fever in rats. Brain Behav Immun. 2008;22(6):838–49.
   PubMed Web of Science ®Google Scholar
• Nishikawa T, Hagihara K, Serada S, Isobe T, Matsumura A, Song J, et al. Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1α is essential for cytokine-driven C-reactive protein gene expression. J Immunol. 2008;180(5):3492–501.
   PubMed Web of Science ®Google Scholar
• Hagihara K, Nishikawa T, Sugamata Y, Song J, Isobe T, Taga T, Yoshizaki K. Essential role of ATAT3 in cytokine-driven NF-kB mediated serum amyloid A gene expression. Genes Cells. 2005; 10(11):1051–63.
   PubMed Web of Science ®Google Scholar
• Raj D. Role of interleukin-6 in the anemia of chronic disease. Semin Arthritis Rheum. 2009;38(5):382–8.
   PubMed Web of Science ®Google Scholar
• Arlet JB, Hermine O, Darnige L, Ostland V, Westerman M, Badoual C, et al. Iron-deficiency anemia in Castleman disease: implication of the interleukin-6/hepcidin pathway. Pediatrics. 2010;126(6):e1608–12.
   Web of Science ®Google Scholar
• Takahashi K, Ohraseki T, Yokouchi Y, Hiruta N, Naoe S. Kawasaki disease as a systemic vasculitis in childhood. Ann Vasc Dis. 2010;3(3):173–81.
   PubMedGoogle Scholar
• Imamura T, Yoshihara T, Yokoi K, Nakai N, Ishida H, Kasubuchi Y. Impact of increased D-dimer concentrations in Kawasaki disease. Eur J Pediatr. 2005;164(8):526–7.
   PubMed Web of Science ®Google Scholar
• Jennewein C, Tran N, Paulus P, Ellinghaus P, Eble JA, Zacharowski K. Novel aspects of fibrin(ogen) fragments during inflammation. Mol Med. 2011;17(5–6):568–73.
   PubMed Web of Science ®Google Scholar
• Levi M. The coagulant response in sepsis and inflammation. Hämostaseologie. 2010;30(1):10–2, 14–6.
   PubMed Web of Science ®Google Scholar
• Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324(23):1633–9.
   PubMed Web of Science ®Google Scholar
• Gupta M, Noel GJ, Schaefer M, Friedman D, Bussel J, Johann-Liang R. Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J Clin Immunol. 2001;21(3):193–9.
   PubMed Web of Science ®Google Scholar
• Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 1997;356(7):663–75.
   Google Scholar
• Reindel R, Shulman ST. Paediatric rheumatology: corticosteroids as primary therapy in Kawasaki disease. Nat Rev Rheumatol. 2012;8(7):373–4.
   PubMed Web of Science ®Google Scholar
• Kanai T, Ishiwata T, Kobayashi T, Sato H, Takizawa M, Kawamura Y, et al. Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: a retrospective study. Circulation. 2011;124(25):2822–8.
   PubMed Web of Science ®Google Scholar
• Matsubara T, Ichiyama T, Furukawa S. Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease. Clin Exp Immunol. 2005;141(3):381–7.
   PubMed Web of Science ®Google Scholar
• Orenstein JM, Shulman ST, Fox LM, Baker SC, Takahashi M, Bhatti TR, et al. Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study. PLoS One. 2012;7(6):e38998.
   PubMed Web of Science ®Google Scholar
• Galeotti C, Bayry J, Kone-Paut I, Kaveri SV. Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun Rev. 2010;9(6):441–8.
   PubMed Web of Science ®Google Scholar
• Mori M, Imagawa T, Katakura S, Miyamae T, Okuyama K, Ito S, et al. Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Mod Rheumatol. 2004;14(1):43–7.
   PubMedGoogle Scholar
• Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Padiatr. 2000;137(2):177–80.
   PubMed Web of Science ®Google Scholar
• Hokosaki T, Mori M, Nishizawa T, Nakamura T, Imagawa T, Iwamoto M, Yokota S. Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease. Pediatr Int. 2012; 54(1):99–103.
   PubMed Web of Science ®Google Scholar
• Ten Cate JW, van der Poll T, Levi M, ten Cate H, van Deventer SJ. Cytokines: triggers of clinical thrombotic disease. Thromb Haemost. 1997;78(1):415–9.
   PubMed Web of Science ®Google Scholar
• van der Poll T, Levi M. Crosstalk between inflammation and coagulation: the lessons of sepsis. Curr Vasc Pharmacol. 2012;10(5):632–8.
   PubMed Web of Science ®Google Scholar
• Ait-Oufella H, Maury E, Lehoux S, Guidet B, Offenstadt G. The endothelium: physiological functions and role in microcirculatory failure during severe sepsis. Intensive Care Med. 2010;36(8):1286–98.
   PubMed Web of Science ®Google Scholar
• Bradham CA, Qian T, Streetz K, Trautwein C, Brenner DA, Lemasters JJ. The mitochondrial permeability transition is required for tumor necrosis factor alpha-mediated apoptosis and cytochrome C release. Mol Cell Biol. 1998;18(11):6353–64.
   PubMed Web of Science ®Google Scholar
• Mehta B, Efthimiou P. Ferritin in adult-onset Still's disease: just a useful innocent bystander?Int J Inflam. 2012; doi: 10.1155/2012/298405
   PubMedGoogle Scholar
• Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005;146(5):662–7.
   PubMed Web of Science ®Google Scholar
• Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008;153(6):833–8.
   PubMed Web of Science ®Google Scholar
• Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, et al. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. J Rheumatol. 2012; 39(4):864–7.
   PubMed Web of Science ®Google Scholar
• Yokota S, Tsubaki K, Kuriyama T, Shimizu H, Ibe M, Mitsuda T, et al. Presence in Kawasaki disease of antibodies to Mycobacterial heat-shock protein HSP65 and autoantibodies to epitopes of human HSP65 cognate antigen. Clin Immunol Immunopathol. 2003;67:163–70.
   Google Scholar
• Rajaiah R, Moudgil KD. Heat-shock proteins can promote as well as regulate autoimmunity. Autoimmun Rev. 2009;8(5):388–93.
   PubMed Web of Science ®Google Scholar
• Sireci G, Dieli F, Salerno A. T cells recognize an immunodominant epitope of heat shock protein 65 in Kawasaki disease. Mol Med. 2000;6(7):581–90.
   PubMed Web of Science ®Google Scholar
• Chun JK, Jeon BY, Kang DW, Kim DS. Bacille Calmette Guérin (BCG) can induce Kawasaki disease-like features in programmed death-1 (PD-1) gene knockout mice. Clin Exp Rheumatol. 2011;29(4):743–50.
   PubMed Web of Science ®Google Scholar
• Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signaling. Mediators Inflamm. 2010; doi: 10.1155/2010/672396
   PubMed Web of Science ®Google Scholar
• Lomaster C, Gerloni V, Gattinara M, Mazzotti J, Cimaz R, Fantini F. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol. 2000;27(2):491–6.
   PubMed Web of Science ®Google Scholar
• Vastert S, Kuis W, Grom AA. Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol. 2009;23(5):655–64.
   PubMed Web of Science ®Google Scholar
• Grom AA, Mellins ED. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol. 2010;22(5):561–6.
   PubMed Web of Science ®Google Scholar
• Takahashi A, Mori M, Naruto T, Nakajima S, Miyamae T, Imagawa T, Yokota S. The role of heme oxygenase-1 in systemic-onset juvenile idiopathic arthritis. Mod Rheumatol. 2009;19(3):302–8.
   PubMed Web of Science ®Google Scholar
• Demirkol D, Yildizdas D, Bayrakci B, Karapinar B, Kendirli T, Koroglu TF, et al. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?Crit Care. 2012;16(2):R52.
   Web of Science ®Google Scholar
• Stephan JL, Zeller J, Hubert P, Herbelin C, Dayer JM, Prieur AM. Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol. 1993;11(4):451–6.
   PubMed Web of Science ®Google Scholar
• Devi S, Consolaro A, Guseinova D, Pistorio A, Ruperto N, Martini A, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2011;38(4):764–8.
   PubMed Web of Science ®Google Scholar
• Grom AA. Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis?Arthritis Rhem. 2004;50(3):689–98.
   PubMed Web of Science ®Google Scholar
• De Jager W, Vastert SJ, Beekman JM, Wulffraat NM, Kuis W, Coffer PJ, Prakken BJ. Defective phosphorylation of interleukin-18 receptor-beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rhem. 2009; 60(9):2782–93.
   PubMed Web of Science ®Google Scholar
• Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med. 2005;15(7):254–9.
   PubMed Web of Science ®Google Scholar
• Vraetx T, Ittel TH, van Mackelenbergh MG, Heinrich PC, Sieberth HG, Graeve L. Regulation of β2-microglobulin expression in different human cell lines by proinflammatory cytokines. Nephrol Dial Transplant. 1999;14(9):2137–43.
   PubMed Web of Science ®Google Scholar
• Bugl S, Wirths S, Muller MR, Radsak MP, Kopp HG. Current insights into neutrophil homeostasis. Ann N Y Acad Sci. 2012;1266:171–8. doi: 10.1111/j.1749-6632.2012.06607
   PubMed Web of Science ®Google Scholar
• Vestweber D. Relevance of endothelial junctions in leukocyte extravasation and vascular permeability. Ann N Y Acad Sci. 2012; 1257:184–92. doi: 10.1111/j.1749-6632.2012.06558
   PubMed Web of Science ®Google Scholar
• Levi M, van der Poll T, ten Cate H. Tissue factor in infection and severe inflammation. Semin Thromb Hemost. 2006;32(1):33–9.
   PubMed Web of Science ®Google Scholar
• Levi M, Schultz M, van der Poll T. Disseminated intravascular coagulation in infectious disease. Semin Thromb Hemost. 2010;36(4):367–77.
   PubMed Web of Science ®Google Scholar
• McMichael M. New models of hemostasis. Top Companion Anim Med. 2012;27(2):40–5.
   PubMed Web of Science ®Google Scholar
• Shibamiya A, Hersemeyer K, Schmidt Woll T, Sedding D, Daniel JM, Bauer S, et al. A key role for Toll-like receptor-3 in disrupting the hemostasis balance on endothelial cells. Blood. 2009;113(3):714–22.
   PubMed Web of Science ®Google Scholar
• Soriano ME, Nicolosi L, Bernardi P. Desensitization of the permeability transition pore by cyclosporine A prevents activation of the mitochondrial apoptosis pathway and liver damage by tumor necrosis factor-alpha. J Biol Chem. 2004;279(35):36803–8.
   PubMed Web of Science ®Google Scholar
• Kota RS, Ramana CV, Tenorio FA, Enelow RI, Rutledge JC. Differential effects of lipoprotein lipase on tumor necrosis factor-alpha and interferon-gamma-mediated gene expression in human endothelial cells. J Biol Chem. 2005;280(35):31076–84.
   PubMed Web of Science ®Google Scholar
• Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicenter, randomized, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis. (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747–54.
   PubMed Web of Science ®Google Scholar
• De Benadetti F, Massa A, Robbioni P. Correlation of interleukin-6 levels with joint involvement and thrombocytosis in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2005;52: 687–93.
   PubMed Web of Science ®Google Scholar
• Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005;52(3):818–25.
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic- onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371(9617):998–1006.
   PubMed Web of Science ®Google Scholar
• Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol. 2005;23:1–21.
   PubMed Web of Science ®Google Scholar
• Hirota H, Yosida K, Kishimoto T, Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA. 1995;92(11):4862–6.
   PubMed Web of Science ®Google Scholar
• Yokota S, Tanaka T, Kishimoto T. Efficacy, safety and tolerqbility of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Muscloskelet Dis. 2012;4(6):387–97.
   PubMedGoogle Scholar
• De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385–95.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396–406.
   PubMed Web of Science ®Google Scholar
• Gross O, Thomas CJ, Guarda G, Tschopp J. The inflammasome: an integrated view. Immunol Rev. 2011;243(1):136–51.
   PubMed Web of Science ®Google Scholar
• Janka G. Hemophagocytic lymphohistiocytosis: when the immune system runs amok. Klin Padiatr. 2009;221(5):278–85.
   PubMed Web of Science ®Google Scholar
• Feldmann J, Prieur AM, Quartier P, Berquin P, Certain S, Cortis E, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet. 2002;71(1):198–203.
   PubMed Web of Science ®Google Scholar
• Yu JR, Leslie KS. Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response. Curr Allergy Asthma Rep. 2011;11(1):12–20.
   PubMed Web of Science ®Google Scholar
• Padeh S. Periodic fever syndromes. Pediatr Clin North Am. 2005;52(2):577–609.
   PubMed Web of Science ®Google Scholar
• Zaki FM, Sridharan R, Pei TS, Ibrahim S, Ping TS. NOMID: The radiographic and MRI features and review of literature. J Radiol Case Rep. 2012;6(3):1–8.
   PubMedGoogle Scholar
• van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med. 2005;5(3):87–98.
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R. Immunology in clinic review series: focus on autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. Clin Exp Immunol. 2012;167(3):391–404.
   PubMed Web of Science ®Google Scholar
• Miller CM, Boulter NR, Fuller SJ, Zakrzewski AM, Lees MP, Saunders BM, et al. The role of the P2X7 receptor in infectious diseases. PLoS Pathog. 2011;7(11):e1002212.
   Web of Science ®Google Scholar
• Dhimolea E. Canakinumab. MAbs. 2010;2(1):3–13.
   PubMed Web of Science ®Google Scholar
• Imagawa T, Nishikomori R, Takada H, Takeshita S, Patel N, Kim D, et al. Safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome: 24-week results from an open-label, phase III pivotal study. Clin Exp Rheumatol. 2013;31(2):302–9.
   PubMed Web of Science ®Google Scholar
• Koné-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, Hachulla E, Leslie KS, Mouy R, et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther. 2011;13(6):R202.
   PubMed Web of Science ®Google Scholar
• Leemans JC, Cassel SL, Sutterwala FS. Sensing damage by the NLRP3 inflammasome. Immunol Rev. 2011;243(1):152–62.
   PubMed Web of Science ®Google Scholar